Deucravacitinib: First Approval
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical)
Link
https://link.springer.com/content/pdf/10.1007/s40265-022-01796-y.pdf
Reference26 articles.
1. Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023–38.
2. Le AM, Puig L, Torres T. Deucravacitinib for the treatment of psoriatic disease. Am J Clin Dermatol. 2022;23:813–22.
3. Nogueira M, Puig L, Torres T. JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors. Drugs. 2020;80(4):341–52.
4. Kim LS, Wu JJ, Han G. Deucravacitinib for psoriasis. Current Dermatology Reports. 2021;10(1):1–5.
5. Bristol Myers Squibb. SOTYKTU™ (deucravacitinib) tablets, for oral use: US prescribing information. 2022. https://packageinserts.bms.com/pi/pi_sotyktu.pdf. Accessed 12 Sep 2022.
Cited by 86 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Discovery and efficacy study of an ALK inhibitor AMX6001 in anaplastic large cell lymphoma Karpas299 mice models;European Journal of Medicinal Chemistry Reports;2024-12
2. Synthetic routes and clinical application of new drugs approved by EMA during 2023;European Journal of Medicinal Chemistry;2024-11
3. Advances in psoriasis research: From pathogenesis to therapeutics;Life Sciences;2024-10
4. Therapeutic inhibition of the JAK-STAT pathway in the treatment of inflammatory bowel disease;Cytokine & Growth Factor Reviews;2024-10
5. Two is better than one: Deuterium in analytical mass spectrometry;TrAC Trends in Analytical Chemistry;2024-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3